Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 multicenter dose-escalation study of NS-035 in Fukuyama-type congenital muscular dystrophy
jRCT2031210252Phase 1Completed
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Sep 2021
- Modality
- Small Molecules, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 1, open-label trial of NS-035 and Bronchitol in Fukuyama congenital muscular dystrophy (FCMD) (4 cohorts), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Safety-related endpoints. Started Sep 2021; status: completed.
02
Drugs
NS-035Bronchitol
03
Conditions
Fukuyama congenital muscular dystrophy (FCMD)
Beyond the preview
Go deeper on jRCT2031210252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210252.